
Respiratory
Latest Content
Latest Videos

Shorts





Podcasts
More News

Real-world data from CHEST 2026 show ETI improved lung function and BMI in children with CF aged 6 to 11, with the most gains in F508del homozygotes.

Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.

Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.

Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk stratification.

Jorgen Vestbo, MD, on the COPERNICOS trial results, long-term antibiotic use versus resistance concerns, and where COPD treatment is headed.

Francesca Puggioni, MD, discusses real-world exacerbations, biomarker-driven access, and barriers to earlier biologic use in asthma and COPD.

Pulmonary experts detail bronchiectasis care gaps, multidisciplinary strategies, and steps toward Care Center Network designation and standardized care.

Based on these results, the investigators are extending their follow-up into adolescence.

Experts at the Washington, DC, Pop Health Roundtable discussed delays in ILD diagnosis, multidisciplinary care, antifibrotic therapy, and insurance barriers.

Steven D. Nathan, MD, explains how recognizing early ILD symptoms, including Velcro crackles and dyspnea, can reduce delays in diagnosis.

Wildfire smoke from US and Canadian fires is worsening air quality, increasing asthma risks and prompting public health guidance.

Doug Francis of Rhythm Healthcare on what's driving respiratory and mobility care out of facilities and into patients' homes

Clesrovimab remained well tolerated through a second RSV season in infants at increased risk of severe RSV.

Voice changes may help detect asthma and COPD exacerbations early, supporting future remote disease monitoring.

Respiratory rehabilitation improved exercise capacity in patients with COPD with and without suspected pulmonary hypertension.

Asthma biologics were associated with sustained reductions in exacerbations after 2015 across demographic and clinical subgroups in a large cohort study.

Joseph K. Han, MD, discusses upstream biologics, verekitug, and the future of chronic rhinosinusitis with nasal polyps treatment.













